Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

Next Previous
X
Search
Trial Profile

Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 May 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms RE2SPOND
  • Sponsors AstraZeneca; Forest Laboratories

    • Most Recent Events

    • 15 May 2018 Pooled analysis results from REACT and RE2SPOND studies (n=4287) were published in the American Journal of Respiratory and Critical Care Medicine
    • 24 May 2017 Results of pooled analysis from REACT and RE2SPOND studies evaluating the efficacy of roflumilast in the overall population and in patients with a history of COPD-related hospitalization presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results assessing effects of roflumilast on cough and sputum production, EXACT-PRO symptom subdomains, presented at the 113th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top